Skip to main content
Premium Trial:

Request an Annual Quote

GlaxoSmithKline to Acquire Cellzome for $99M

NEW YORK (GenomeWeb News) – GlaxoSmithKline today said that it has reached an agreement to acquire the remaining 80 percent of proteomics firm Cellzome that it didn't already own for £61 million ($99 million).

The deal will provide GSK with state-of-the-art proteomic mass spectrometry and screening capabilities, the UK drug firm said. It will use Cellzome's technologies to assess drug interactions with target proteins and to help identify potential safety issues earlier in the drug discovery process.

"The acquisition of Cellzome adds significantly to our scientific capabilities and capacity to characterize drug targets and provides the opportunity to further enhance GSK's ability to bring medicines to patients in a more effective manner," John Baldoni, SVP of platform and technology science at GSK, said in a statement.

GSK already held a 19.98 percent stake in Cellzome, will become part of GSK's R&D organization. The deal is expected to close next week.

GSK also said that it will create a spin-off company, which would hold the rights to certain of Cellzome's assets and activities that GSK does not wish to progress.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.